Oculis Holding AG (NasdaqGM: OCS)
Health Care · Pharmaceuticals · CH
$12.83
-1.00% today · -26.1% 1Y
Oculis Holding AG (NasdaqGM: OCS) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $800.05M and employs 60 people.
Over the last twelve months the share price has lost 26.1%, trading between 10.52 and 34.48.
Tweenvest scores Oculis Holding AG across four factors: quality 26/100, value 40/100, growth 28/100. Its strongest factor is value.
OCS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $800.05M
- Revenue (TTM)
- $1.45M
- P/E
- —
- EPS
- -1.39
- Dividend yield
- —
- Beta (5Y)
- 0.23
- 52-week high
- $34.48
- 52-week low
- $10.52
- Avg volume (3M)
- —
- Shares outstanding
- 61.73M
- Employees
- 60
- Next earnings
- —
About Oculis Holding AG
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
- ISIN
- CH1242303498
- Founded
- 2017
- Listed since
- May 18, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,226.58 | -0.57% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.58 | -0.57% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.68 | -1.77% |
| Roche Holding AGSWX: ROP | $371.62B | CHF369.70 | -1.10% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.92 | -1.47% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.35 | -0.77% |
Figures last refreshed Aug 18, 2026.